Relationships among plasma [2-13C]uracil concentrations, breath 13CO2 expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and DPD-deficient dogs

Drug Metabolism and Disposition

Volumn 33, Issue 3, 2005, Pages 381-387

  Inada, Makoto ^a,b   Hirao, Yukihiro ^b   Koga, Toshihisa ^b   Itose, Minoru ^a,b   Kunizaki, Jun Ichi ^a   Shimizu, Takefumi ^a   Sato, Hitoshi ^c  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b Tokushima Research Institute   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL)URACIL; CARBON 13; DIHYDROPYRIMIDINE DEHYDROGENASE; ENZYME INHIBITOR; UNCLASSIFIED DRUG; URACIL; URACIL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARBON DIOXIDE EXCRETION; CONTROLLED STUDY; DOG; DOSE RESPONSE; ENZYME ACTIVITY; INTERMETHOD COMPARISON; LIVER; LIVER CYTOSOL; MALE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BREATH TESTS; BROMOURACIL; CARBON DIOXIDE; CARBON ISOTOPES; DIHYDROURACIL DEHYDROGENASE (NADP); DOGS; INJECTIONS, INTRAVENOUS; LIVER; MALE; URACIL;

EID: 14044264190     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001032     Document Type: Article

References (27)

1. Almersjo OE, Gustavsson BG, Regardh CG, and Wahlen P (1980) Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. Acta Pharmacol Toxicol (Copenh) 46:329-336.
2. Collie-Duguid ES, Etienne MC, Milano G, and McLeod HL (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10:217-223.
3. Collins JM (1985) Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species. Cancer Chemother Pharmacol 14:108-111.
4. Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F, and Bricaud H (1986) Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 46:1094-1101.
5. Diasio RB and Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237.
6. Duschinsky R, Pleven E, and Heidelberger C (1957) The synthesis of 5-fluoropyrimidines. J Am Chem Soc 79:4559-4560.
7. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, and Milano G (1995) Response to fluorouracil therapy in cancer patients: role of tumoral dihydropyrimidine dehydrogenase. J Clin Oncol 13:1663-1670.
8. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, and Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902.
9. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 47:2203-2206.
10. Ho DH, Townsend L, Luna MA, and Bodey GP (1986) Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6:781-784.
11. Johnson MR, Yan J, Shao L, Albin N, and Diasio RB (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696:183-191.
12. Khor SP, Amyx H, Davis ST, Nelson D, Baccanari DP, and Spector T (1997) Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. Cancer Chemother Pharmacol 39:233-238.
13. Kuan HY, Smith DE, Ensmiger WD, Knol JA, DeRemer SJ, Yang Z, and Stetson PL (1996) Regional pharmacokinetics of 5-bromo-2′-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions. Cancer Res 56:4724-4727.
14. Lyss AP, Lilenbaum RC, Harris BE, and Diasio RB (1993) Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Investig 11:239-240.
15. Morrison GB, Bastian A, Dela Rosa T, Diasio RB, and Takimoto CH (1997) Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 24:83-88.
16. Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, and Ohnishi Y (1997) Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7:35-43.
17. Nishiyama T, Ogura K, Okuda H, Suda K, Kato A, and Watabe T (2000) Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH. Mol Pharmacol 57:899-905.
18. Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, and Watabe T (1997) Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 25:270-273.
19. Okuda H, Ogura K, Kato A, Takubo H, and Watabe T (1998) A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 287:791-799.
20. Pinedo HM and Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664.
21. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, et al. (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46:151-156.
22. Sawai Y, Yamaoka K, Ito T, and Nakagawa T (1997) Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. Biol Pharm Bull 20:1313-1316.
23. Shand DG, Kornhauser DM, and Wilkinson GR (1975) Effects of route of administration and blood flow on hepatic drug elimination. J Pharmacol Exp Ther 195:424-432.
24. Sludden J, Hardy SC, VandenBranden MR, Wrighton SA, and McLeod HL (1998) Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse. Pharmacology 56:276-280.
25. Sumi S, Kidouchi K, Kondou M, Hayashi K, Dobashi K, Kouwaki M, Togari H, and Wada Y (1998) Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine. Int J Mol Med 2:477-482.
26. Sumi S, Kidouchi K, Ohba S, and Wada Y (1995) Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 672:233-239.
27. Woodcock TM, Martin DS, Damin LA, Kemeny NE, and Young CW (1980) Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer 45:1135-1143.